Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965170 · ClinicalTrials.gov registry record
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
A clinical trial, sponsored by Rocky Mountain MS Research Group.
- Completed
- Registry status
- 109
- Enrollment target
NCT02965170 is a clinical trial that has completed, run by Rocky Mountain MS Research Group. The registered enrollment target is 109 participants.
The verdict
NCT02965170 has completed, sponsored by Rocky Mountain MS Research Group.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
Validating a peptide-based laboratory test enabling the measurement of Tysabri® serum levels (pharmacokinetics, PK) in multiple sclerosis patients undergoing therapy. The results of this newly developed test will be compared to Tysabri® serum levels measured in parallel using an independent test. We will also simultaneously measure a pharmacodynamic marker of Tysabri®, receptor saturation levels on blood immune cells, which is thought to correlate with Tysabri® serum levels.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02965170
The ClinicalTrials.gov registry entry for NCT02965170 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rocky Mountain MS Research Group, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02965170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02965170 about?
NCT02965170 is a clinical study titled "Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS". Validating a peptide-based laboratory test enabling the measurement of Tysabri® serum levels (pharmacokinetics, PK) in multiple sclerosis patients undergoing therapy. The results of this newly developed test will be compared to Tysabri® serum levels measured in parallel using an independent test. We...
What is the current status of trial NCT02965170?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2016-10. Estimated completion is 2018-05.
Who is sponsoring clinical trial NCT02965170?
This trial is sponsored by Rocky Mountain MS Research Group, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.